卫材与参天制药签署眼科新药开发协议 发布时间：2012-9-27 来源：药品资讯网信息中心卫材(Eisai)与参天制药(Santen PHarmaceuticals)今天宣布，双方已签订了一份选择权(option)协议，授予参天制药有关卫材眼科领域化合物的临床开发评价权利及第一协商权(first negotiation)。参天制药是一家专门从事眼科和抗风湿/骨关节疾病领域新药研发的公司，致力于维护人们的视力和健康，在眼科领域积累了丰富的经验和成就。根据协议条款，卫材将授予参天制药评价卫材眼科领域化合物临床开发可行性的权利，以及有关所选择的任何化合物的第一协商权利，同时参天制药将支付一笔一次付清的预付款。通过该项协议，参天制药有望增强其眼科领域药物管线，同时能够节省时间，将这些有前景的化合物带入I期临床开发。此外，通过将化合物授权给参天制药，卫材将能够进一步发挥出其化合物的最大价值。在合同关系的基础上，这2家公司将利用卫材的化合物及参天制药在眼科领域的优势，来加快创造新的药物用于眼科疾病治疗，从而为满足多样性的医疗需求做出更大的贡献。
Santen in ophthalmics deal with Eisai; Sets up new company in China
Article | 26 September 2012 Japan's Santen Pharmaceutical (TYO: 4536) has entered into an option agreement with drug major Eisai (TYO: 4523) to gain rights of evaluation and first negotiation for Eisai-owned compounds in the field of ophthalmology. Under the terms of the accord, Eisai will grant Santen the rights to evaluate the feasibility of developing compounds disclosed by Eisai for use in the ophthalmologic field within a certain period as well as the rights of first negotiation for a license agreement concerning any selected compound. In consideration of the granted rights, Santen will pay Eisai a lump-sum payment up-front. Further financial terms were not disclosed. In cases where license agreements are concluded based on the terms of this deal, Santen will be able to apply in the ophthalmologic field any compounds for which efficacy, safety and other data have been accumulated, and as a result, can expect to enhance its ophthalmology pipeline and reduce the time it takes to bring the respective compounds to Phase I clinical development. Furthermore, by licensing out compounds to Santen, a company that has built up a wealth of experience and achievements in the ophthalmology field, Eisai will be able to further maximize the value of its compounds. Based on this contractual relationship, the two companies seek to leverage Eisai's compounds and Santen's strengths in the field of ophthalmology to expedite the creation of innovative new drugs to treat ophthalmic diseases.
New sales and marketing company in China Separately, Santen announced that it will establish a new, wholly-owned sales and marketing company at this stage (dubbed Newco for the time being) in China, which will apply for a drug distribution permit in China, and when Newco obtains such permit, the sales and marketing function of existing subsidiary Santen Pharmaceutical (China) will be transferred to Newco. Currently Santen can only sell and market products manufactured by Santen China, however, on gaining the permit, Newco will be able to import finished products as well as sell and market products manufactured by third parties. Santen expects to enhance its product line-up in China through Newco, in order to meet the needs of patients in China. Use of funds with respect to the paid in capital of Newco will be for the construction of the automated distribution warehouse. Under its long term strategic vision, Santen aims to become a "specialized pharmaceutical company with a global presence" by year 2020. It also aims to expand its business in China, under its Medium-term Management Plan 2011-2013.
Posts
No comments:
Post a Comment